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(PIBACKGROUND Anthracycline-induced cardiotoxicity is a major clinical problem, and early cardiotoxicity markers are
needed.
OBJECTIVES The purpose of this study was to identify early doxorubicin-induced cardiotoxicity by serial multipara-
metric cardiac magnetic resonance (CMR) and its pathological correlates in a large animal model.
METHODS Twentypigswere included.Of these, 5 received5biweekly intracoronary doxorubicindoses (0.45mg/kg/injection)
and were followed until sacriﬁce at 16 weeks. Another 5 pigs received 3 biweekly doxorubicin doses and were followed to
16weeks.A thirdgroupwassacriﬁced after the thirddose.All groupsunderwentweeklyCMRexaminations including anatomical
andT2 andT1mapping (including extracellular volume [ECV] quantiﬁcation). A control groupwas sacriﬁcedafter the initial CMR.
RESULTS The earliest doxorubicin-cardiotoxicity CMR parameter was T2 relaxation-time prolongation at week 6
(2 weeks after the third dose). T1 mapping, ECV, and left ventricular (LV) motion were unaffected. At this early time point,
isolated T2 prolongation correlated with intracardiomyocyte edema secondary to vacuolization without extracellular
space expansion. Subsequent development of T1 mapping and ECV abnormalities coincided with LV motion defects: LV
ejection fraction declined from week 10 (2 weeks after the ﬁfth and ﬁnal doxorubicin dose). Stopping doxorubicin therapy
upon detection of T2 prolongation halted progression to LV motion deterioration and resolved intracardiomyocyte
vacuolization, demonstrating that early T2 prolongation occurs at a reversible disease stage.
CONCLUSIONS T2 mapping during treatment identiﬁes intracardiomyocyte edema generation as the earliest
marker of anthracycline-induced cardiotoxicity, in the absence of T1 mapping, ECV, or LV motion defects. The
occurrence of these changes at a reversible disease stage shows the clinical potential of this CMR marker for
tailored anthracycline therapy. (J Am Coll Cardiol 2019;73:779–91) © 2019 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).A nthracyclines are highly effective andfrequently used chemotherapy drugs (1),with the most commonly used being doxoru-
bicin, alone or in combination with other anticancer
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780cancer and chronic heart failure places an
immense personal burden on patients, with
physical and psychological consequences.
Anthracyclines bind to topoisomerase 2b
in the cardiomyocyte’s DNA. Anthracyclines-
topoisomerase 2b complexes bind to pro-
moters of mitochondrial antioxidative,
biogenesis, and electron transport chain
genes leading to a downstream mitochon-
drial dysfunction. In fact, genetic ablation of
topoisomerase 2b in mice ameliorates
anthracycline-induced cardiotoxicity (3). In
addition, anthracyclines bind to cardiolipinin the inner mitochondrial membrane, contributing to
increased reactive oxygen species generation, iron
deposition, and defective mitochondrial biogenesis
(3,4). Altogether, these phenomena lead to mito-
chondrial swelling, intracardiomyocyte vacuoliza-
tion, and ultimately, cell death and replacement of
cardiomyocytes by ﬁbrotic tissue (5–7).SEE PAGE 792Current algorithms to identify early stages of
anthracycline-induced cardiotoxicity are far from
optimal. Diagnosis generally occurs once left ven-
tricular (LV) functional deterioration becomes mani-
fest, either as a decline in left ventricular ejection
fraction (LVEF) or longitudinal LV strain abnormal-
ities (8,9). By this stage, the damage to the myocar-
dium is often irreversible. The lack of a validated
early damage marker limits the development of pre-
ventive strategies. Cardiac magnetic resonance (CMR)
is the gold standard technique for anatomical and
functional evaluation of the heart, and the advent of
multiparametric algorithms allows accurate charac-
terization of myocardial tissue. CMR is thus suitable
for the detection of myocardial edema (10–12) and
diffuse myocardial ﬁbrosis (13–15), which are present
at different stages of anthracycline-induced car-
diotoxicity (16–21). To date, there has been a lack of
comprehensive serial multiparametric CMR tissue
studies characterizing the full anthracycline treat-
ment cycle from pre-treatment, through treatment, to
overt LV systolic dysfunction and heart failure.cardiology grant). This research program is part of an institutiona
az. This study forms part of a Master Research Agreement betwe
search program between Hospital de Salamanca Cardiology Depa
de Ciencia, Innovación y Universidades, and the Pro-CNIC Foun
rd SEV-2015-0505). Drs. Galán-Arriola and Villena-Gutierrez are P
énez has received funding through the European Union Horizon
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ships relevant to the contents of this paper to disclose.
received August 13, 2018; revised manuscript received October 1Here, we used a large animal model (pig) of
doxorubicin-induced cardiotoxicity to identify the
earliest CMR marker of myocardial damage and its
pathological correlates. We also studied the revers-
ibility of cardiotoxicity upon detection of the early
CMR marker.
METHODS
STUDY DESIGN. The study was approved by the
Institutional Animal Research Committee and con-
ducted in accordance with recommendations of the
Guide for the Care and Use of Laboratory Animals.
The study design is summarized in Figure 1. The study
population consisted of 20 castrated male large white
pigs (25 to 35 kg). Pigs in group 1 received 5 biweekly
doxorubicin injections (ﬁnal injection at week 8) and
were followed-up until sacriﬁce at week 16 by intra-
venous injection of pentobarbital sodium in over-
dose. In group 2, pigs underwent 3 biweekly
doxorubicin injections (ﬁnal injection at week 4) and
were similarly followed-up until sacriﬁce at week 16.
Group 3 pigs underwent the same doxorubicin pro-
tocol as group 2 (3 biweekly injections) but were
sacriﬁced earlier, at week 6 (2 weeks after the ﬁnal
doxorubicin injection). Group 4 was a control group
sacriﬁced after baseline CMR without doxorubicin
exposure. In all groups, weekly comprehensive mul-
tiparametric CMR examinations were performed until
sacriﬁce. In the treatment weeks, CMR scans were
performed immediately before doxorubicin
injections.
DOXORUBICIN ADMINISTRATION PROCEDURE. We
used a modiﬁcation of a previously described
approach (22,23). Animals were anesthetized and
endotracheally intubated. The femoral artery was
then accessed by the Seldinger technique, and a 7-F
sheath was inserted. Pigs were anticoagulated with
150 IU/kg of intravenous heparin, and a 5-F coronary
diagnostic catheter was inserted via a femoral sheath
and placed at the origin of the left coronary artery.
Under angiography guidance, a 0.014-mm coronary
guidewire was positioned distally in the left anterior
descending (LAD) coronary artery. The catheter wasl agreement between the CNIC and FIIS-Fundación
en the CNIC and Philips Healthcare, and is part of a
rtment and the CNIC. The CNIC is supported by the
dation, and is a Severo Ochoa Center of Excellence
-FIS fellows (Instituto de Salud Carlos III). Dr. Fer-
2020 Research and Innovation program under grant
care. All other authors have reported that they have
4, 2018, accepted November 8, 2018.
FIGURE 1 Study Design
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Large white castrated male pigs weighing 25 to 30 kg were used in this study. Animals were divided into 4 experimental groups of 5 animals
each. Group 1 animals received 5 biweekly intracoronary (IC) doxorubicin (doxo) doses followed by 8 dose-free weeks, whereas Group 2 pigs
received 3 biweekly IC doxo doses followed by 12 dose-free weeks. Group 3 pigs received 3 IC doxo dose followed by 2 dose-free weeks before
sacriﬁce. Group 4 was a control group of untreated animals. Cardiac magnetic resonance scans were performed every week in each group,
before doxo infusion. Infused and remote myocardial areas were collected at sacriﬁce for further analysis.
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781docked selectively in the LAD, and a 0.45 mg/kg dose
of doxorubicin (Farmiblastina, Pﬁzer, New York, New
York) diluted in 30 ml saline was given as a slow bolus
injection over 3 min. Electrocardiographic and
hemodynamic monitoring was maintained during
doxorubicin administration. Once the infusion was
completed, coronary angiography was performed to
document normal coronary ﬂow, the catheter mate-
rial was removed, and the animal was allowed to
recover.
CMR PROTOCOL. All studies were performed with a
Philips 3-T Achieva Tx whole body scanner (Philips
Healthcare, Best, the Netherlands) equipped with
a 32-element phased-array cardiac coil. The CMR
protocol included a standard segmented cine
steady-state free-precession sequence to provide
high-quality anatomical references, a T2 gradient-
spin-echo mapping sequence, and native and
post-contrast T1 mapping and late gadolinium
enhancement (LGE) sequences.
The imaging parameters for the standard segmented
cine steady-state free-precession sequence were as
follows: ﬁeld of view (FOV) of 280  280 mm, slice
thickness 6 mm with no gaps, repetition time (TR)
2.8 ms, echo time (TE) 1.4 ms, ﬂip angle 45, cardiac
phases ¼ 30, voxel size 1.8  1.8 mm, and number ofexcitations ¼ 3. The imaging parameters for the
T2-gradient-spin-echo mapping sequence mapping were
FOV 300  300 mm with an acquisition voxel size of
1.8  2.0 mm2 and slice thickness 8 mm, and 8 echo
times ranging from 6.7 to 53.6 ms. To reduce T1 effects, a
2-heartbeat interval was used between excitations. The
T1 mapping sequence (Modiﬁed Look-Locker Inversion
recovery [MOLLI]) was acquired before and 10 min after
contrast administration. All MOLLI sequences were
based on a 5(3)3 scheme using a single shot steady-state
free precession readout sequence (TR/TE/ﬂip
angle ¼ 2.1 ms/1.05 ms/35) with an in-plane acquisition
resolution of 1.5  1.8 mm2 and an 8-mm slice thickness.
T2 and T1 mapping sequences were both triggered at
mid-diastole and acquired from a single short-axis
midapical slice.
LGE imaging was performed 15 min after intrave-
nous administration of 0.2 mmol/kg gadopentetate
dimeglumine contrast agent using an 3-dimensional
inversion-recovery spoiled turbo ﬁeld echo
sequence (TR/TE/ﬂip angle ¼ 2.4 ms/1.13 ms/10) with
an isotropic resolution of 1.5  1.5  1.5 mm3 on a FOV
of 340  340  320 mm3 in the FH, LR, and AP
directions. Data were acquired in mid-diastole with a
151.2-ms acquisition window. Acquisition was accel-
erated using a net SENSE factor of 2.25 (1.5  1.5 in the
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782AP and LR directions) with a bandwidth of 853 Hz per
pixel. Inversion time was adjusted before acquisition
using a look-locker scout sequence with different
inversion times to ensure proper nulling of
the healthy myocardium signal. For the analysis,
3-dimensional volume was reconstructed in short-
axis, 2-chamber, and 4-chamber views with a slice
thickness of 6 mm.
CMR ana lys i s . CMR studies were analyzed by 2
experienced and independent observers using dedi-
cated software (MR extended Work Space 2.6, Philips
Healthcare; and Qmass MR 7.6, Medis, Leiden, the
Netherlands). T2 maps were automatically generated
on the acquisition scanner by ﬁtting the signal in-
tensity of all echo times to a monoexponential decay
curve at each pixel with a maximum likelihood
expectation maximization algorithm. T1 maps were
generated using a maximum-likelihood expectation-
maximization algorithm and ﬁtting the MR signal to a
T1 inversion recovery with 3 independent model
parameters. T2 and T1 relaxation maps were quanti-
tatively analyzed by placing a wide transmural region
of interest at the infused myocardial area (irrigated by
the LAD) of the corresponding slice in all studies.
Delayed gadolinium-enhanced regions were deﬁned
as >50% of maximum myocardial signal intensity
(full width at half maximum) and qualitatively
analyzed. Extracellular volume (ECV) was estimated
with native T1-MOLLI values and 10-min post-
contrast T1-MOLLI values corrected by hematocrit,
as described elsewhere (13).
Ex-v ivo analys i s . After heart extraction, samples of
the doxorubicin-infused region (anteroseptal wall)
and the remote area were collected for histology and
water content quantiﬁcation. For histological studies,
samples were ﬁxed in 4% formalin and then trans-
ferred to 70% ethanol. After parafﬁn embedding,
4-mm sections were cut and stained with hematoxylin
and eosin, Masson trichrome, and Sirius Red. Stained
sections were scanned, and 20  20 magniﬁcation
images were taken for collagen quantiﬁcation using a
modiﬁed macro (24).
For water content quantiﬁcation, harvested tissue
samples were immediately blotted to remove surface
moisture and then introduced into laboratory crystal
containers previously weighed on a high-precision
scale. The tissue-loaded containers were weighed
before and after drying for 48 h at 100C in a desic-
cating oven. Tissue water content (% dry weight) was
calculated using the following formula: water
content ¼ ([wet weight  dry weight]/dry weight) 
100. An empty container was weighed before and
after desiccation as an additional calibration control.STATISTICAL ANALYSIS. Sample size selection. Objective
1 was hypothesis generating, and for this reason, we
used an arbitrary same sample size of 5 animals
(similar to previous hypothesis-generating pig
studies [25]). For objective 2, we based the sample
size selection on results (T2 relaxation times) from
objective 1, and on the capacity to detect a
meaningful 5-ms difference in T2 relaxation time
between examination time points. Taking into
consideration an anticipated SD of 3 ms, and
multiple pairwise comparisons between time points,
a sample size of 5 individuals/group resulted in a
statistical power of 80% to detect differences.
Variables are expressed as mean  SD or median
(interquartile range [Q1, Q3]) as appropriate. Data
normality was assessed with the Shapiro-Wilk test.
The Student’s t-test was used for 2-group com-
parisons, and the changes of imaging variables
across time was assessed using 1-way repeated
measures analysis of the variance test. To identify
the timepoints showing statistically signiﬁcant
changes compared with the baseline values, pairwise
paired Student’s t-tests were performed taking into
account p value adjustment for multiple compari-
sons (Bonferroni method). Differences were consid-
ered statistically signiﬁcant at p < 0.05. All data
were analyzed with RStudio (RStudio Team [2015],
Integrated Development for RStudio, Inc., Boston,
Massachusetts), and graphics were created with
ggplot2.
RESULTS
None of the pigs showed adverse events during
doxorubicin administration at any time point (i.e., no
changes were noted in electrocardiogram or systolic
arterial pressure during injections). None of the pigs
died during the study.
SERIAL CMR TISSUE CHARACTERIZATION OF
DOXORUBICIN-INDUCED CARDIOTOXICITY. A total
of 5 pigs received 5 biweekly doxorubicin injections
(weeks 0, 2, 4, 6, and 8). Multiparametric CMR was
performed weekly until week 16, when animals were
sacriﬁced and hearts were harvested for pathology
evaluation.
LV eject ion fract ion . Weekly CMR examinations
revealed no changes in LVEF until week 9 (1 week
after the ﬁfth and ﬁnal doxorubicin injection). From
week 9 onwards, LVEF declined progressively, the
decline becoming signiﬁcant at week 12 (55  4% at
baseline vs. 33  6% at week 12; p < 0.01). The
lowest LVEF value was recorded at the 16-week time
point (30  8%; p ¼ 0.01 vs. baseline). Group and
FIGURE 2 Animal Model of Anthracycline Cardiotoxicity (Group 1)
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(A) Time course of cardiac magnetic resonance (CMR) imaging studies. Data are represented as mean  SD (bars). (B) Individual animal data at
selected time points for left ventricular ejection fraction (LVEF), T2, and extracellular volume (ECV). Asterisks indicate statistically signiﬁcant
differences compared with week 0: *p < 0.05, **p < 0.01.
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783individual LVEF trajectories are presented in
Figures 2A and 2B. LVEF data are presented in Online
Table 1. In agreement with the LVEF data, no
regional contractile abnormalities were documented
until week 12, when the doxorubicin-infused
myocardium showed regional wall motion defects
(data not shown).
T2 re laxat ion t imes . Weekly CMR examinations
revealed no changes in T2 relaxation times on CMR
examinations performed at weeks 0 through 5. Atweek 6, T2 relaxation times were signiﬁcantly longer
than at baseline (45.2  0.5 ms and 52.0  1.4 ms at
baseline and week 6, respectively; p ¼ 0.007). T2
relaxation times subsequently increased, reaching a
maximum at end follow-up (73.0  4.6 ms and 72.8 
4.6 ms on weeks 12 and 16; p ¼ 0.003 and p ¼ 0.001 vs.
baseline, respectively). Group and individual T2
trajectories are presented in Figures 2A and 2B.
T2 relaxation times at all time points are presented in
Online Table 1.
FIGURE 3 Time Course CMR Comparison Between Groups 1 and 2
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(A) LVEF (%). (B) T2-gradient-spin-echo (T2-GraSE) mapping sequence in the infused area (in ms). (C) ECV in the infused area (%). (D) Representative images of late
gadolinium enhancement sequences for selected time points and groups. (E) Representative images of T2-GraSE mapping for selected time points and groups,
represented with a masked range (20 to 120 ms). (F) Representative images of native T1-MOLLI mapping for selected time points and groups, represented with a
masked range (550 to 1,750 ms). Abbreviations as in Figure 2.
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784T1 re laxat ion t imes . Native T1 relaxation times
showed no change from baseline until week 10
(2 weeks after the ﬁfth and ﬁnal doxorubicin dose). A
nonsigniﬁcant increase was noted at week 10, fol-
lowed by a progressive increase to end follow-up at
week 16. Native T1 values were signiﬁcantly longer
than at baseline only from week 12 onwards (1,087 
101 ms and 1,220  59 ms at baseline and week 12
respectively; p ¼ 0.02). Group and individual native
T1 trajectories are presented in Online Figures 1A and
1C. Complete T1 relaxation time data are presented in
Online Table 1.
Extrace l lu lar volume. ECV expansion was tracked
using a validated formula that includes pre- and post-
contrast T1 values and hematocrit (13). In parallel with
the native T1 trajectory, ECV did not differ from
baseline until week 10 (2 weeks after the ﬁfth and
ﬁnal doxorubicin dose). ECV subsequently expandedprogressively, but with no statistically signiﬁcant
difference from baseline until week 14 (26.03  5.81%
and 41  1.34% at baseline and week 14, respectively;
p ¼ 0.006). Group and individual ECV trajectories are
presented in Figures 2A and 2C. Complete ECV data
are presented in Online Table 1. Post-contrast T1
relaxation times are presented in Online Figures 1B
and 1C.
Late gadol in ium enhancement . Positive LGE areas
ﬁrst appeared in the doxorubicin-infused area from
week 10 onwards. The enhanced areas formed a pat-
chy pattern at week 12, becoming more evident at
16 weeks follow-up (Figure 3D).
T2-DRIVEN STRATEGY FOR THE PREVENTION OF
ANTHRACYCLINE-INDUCED CARDIOTOXICITY. Hav-
ing documented T2 mapping abnormalities preceding
systolic function deterioration, we next explored
whether T2 relaxation time prolongation occurred at a
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785reversible stage of anthracycline-induced cardiotox-
icity. To address this question, we studied a group of
5 pigs (group 2) in which doxorubicin treatment was
stopped upon detection of T2 prolongation. As in
group 1, T2 relaxation times in group 2 pigs were
nonsigniﬁcantly prolonged at week 5 and this pro-
longation became signiﬁcant at week 6 (i.e., imme-
diately before the scheduled fourth doxorubicin
dose). Group 2 pigs therefore received only 3 doxo-
rubicin doses (weeks 0, 2, and 4) and were followed-
up until week 16. T2 relaxation times in group 2 pigs
were signiﬁcantly prolonged at week 6 (45.6  0.6 ms
and 51.6  0.8 ms at baseline and week 6, respec-
tively; p ¼ 0.004) but returned to baseline levels at
week 8 (45.5  1.3 ms; p ¼ 1.00 vs. baseline), and
these levels were maintained until the end of follow-
up (44.8  1.4 ms at week 16; p ¼ 1.00 vs. baseline)
(Figure 3B and 3E, red lines). LVEF in group 2 showed
no deterioration during follow-up (Figure 3A), and
regional LV wall motion was similarly unaffected. All
other evaluated parameters in group 2 remained
within normal ranges throughout follow-up (Figure 3,
red lines, and Online Table 1).
PATHOLOGICAL CORRELATES OF EARLY T2
MAPPING CHANGES. The underlying tissue compo-
sition changes leading to early T2 relaxation-time
prolongation in the presence of normal T1 and ECV
readings was investigated in another group of 5 pigs
(Group 3). Group 3 animals received 3 doxorubicin
doses at weeks 0, 2, and 4, and were sacriﬁced
immediately after detection of T2 prolongation (at
week 6). Like the other groups, these animals un-
derwent a weekly CMR examination. Tissue samples
from group 3 animals were compared with samples
from groups 1 and 2 animals, which were sacriﬁced at
the end of the 16-week protocol.
Myocard ia l water content . As expected, T2
relaxation-time prolongation was associated with an
increase in myocardial water content (10). At week 6,
after 3 doxorubicin doses, T2 relaxation times were
signiﬁcantly prolonged in group 3 animals (45.8 
2.52 ms and 52.6  2.2 ms at baseline and week 6,
respectively; p ¼ 0.01) (Figures 3B and 3E, gray lines).
Myocardial water content was signiﬁcantly elevated
in samples harvested at this time point (396  12% of
dry weight and 375  0.7% in group 3 and control,
respectively; p ¼ 0.014) (Figure 4C). ECV CMR data for
group 3 revealed no expansion of the extracellular
space at week 6 (Figures 3C and 3F, gray line), indi-
cating that the increased myocardial water content
and T2 prolongation likely corresponds to intracel-
lular edema.At the end of follow-up in group 1 (5 biweekly
doxorubicin doses followed by sacriﬁce at week 16),
myocardial water content was also signiﬁcantly
increased (500  39% of dry weight; p < 0.001 vs.
control). At this time point, ECV CMR data revealed
an overt increase in extracellular space (Figures 3C
and 3F, blue line), a ﬁnding compatible with extra-
cellular edema formation. This is consistent with the
positive LGE at this disease stage (Figure 3D). Inter-
estingly, myocardial end follow-up water content in
group 2 (3 biweekly doxorubicin doses and follow-up
to week 16) did not differ from control subjects (365 
0.5%; p ¼ 0.13 vs. control). Myocardial water content
in all groups is shown in Figure 4C.
Structura l myocard ia l changes . Hematoxylin and
eosin staining of group 3 samples (harvested at week
6, after 3 doxorubicin doses) revealed cardiomyocyte
vacuolization (Figure 4E, left panel) with no other
overt alteration to myocardial tissue structure; car-
diomyocytes maintained their shape, and there was
no increase in extracellular space. Interestingly, at
16-week follow-up of animals receiving 3 doxorubicin
doses (group 2), samples showed no intra-
cardiomyocyte vacuolization (Figure 4E, right panel).
Conversely, myocardial samples from group-1 pigs (5
doxorubicin doses and 16-week follow-up) showed
even larger intracardiomyocyte vacuolae and a dis-
arrayed myocardial structure, with increased extra-
cellular space and replacement ﬁbrosis, suggestive of
end-stage disease (Figures 4A and 4E, middle panel).
Complete histopathology data (ﬁbrosis, myocardial
water content, and vacuolae presence) and CMR data
(ECV and T2 relaxation times) are shown for all groups
and sacriﬁce time points in Figure 4.
DISCUSSION
In a pig model of anthracycline-induced cardiotox-
icity with serial multiparametric CMR evaluations,
we demonstrate that T2 mapping abnormalities pro-
vide the earliest marker of subtle myocardial dam-
age, with T2 relaxation times prolonged long before
LV motion abnormalities were detected (Central
Illustration). At this early stage of cardiotoxicity, T1
relaxation times and ECV quantiﬁcation were unal-
tered. Pathology evaluation upon T2 prolongation
demonstrated an absolute increase in myocardial
water content, correlating with vacuolae formation
in preserved cardiomyocytes but with no concomi-
tant ﬁbrosis or increased extracellular space. These
ﬁndings demonstrate that T2 relaxation-time pro-
longation in the presence of normal T1 mapping and
ECV identiﬁes intracardiomyocyte edema as the
FIGURE 4 End Follow-Up Ex Vivo and Imaging Studies of the Infused Area in Each Group
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787earliest anthracycline-induced cardiotoxic event.
Our results further demonstrate that stopping
doxorubicin administration upon detection of T2
relaxation-time prolongation prevents progression
to myocardial dysfunction, with subsequent T2
normalization as a surrogate of cardiomyocyte
vacuolae resolution. These ﬁndings indicate that this
marker of intracardiomyocyte edema appears at a
reversible disease stage and, thus, has important
clinical implications.
Previous CMR evaluations of anthracycline-
induced cardiotoxicity have been performed in mice
(26), rats (27,28), and rabbits (29,30); however, ours is
the ﬁrst study to use the pig model with serial CMR
evaluations. We chose the pig because of its
anatomical and physiological similarity to humans
(including heart rate and metabolism) and because
the CMR protocols are the same as those used clini-
cally. Our study is the most comprehensive to date,
because it includes weekly multiparametric CMR
evaluations over 4 months to cover all cardiotoxicity
stages, from baseline to end-stage disease with overt
LVEF deterioration. Following a modiﬁcation of a
published protocol in pigs (22,23), doxorubicin was
injected directly into the coronary arteries rather than
intravenously. This approach achieves high local
doxorubicin concentrations in the heart without
exposing animals to undesired systemic adverse ef-
fects like myelosuppression, which would render the
animals vulnerable to infection and thus potentially
affect survival and even cardiac readouts. This
approach is validated by the absence of casualties in
our study.
Current clinical approaches for the early detection
of cardiotoxicity are based on deterioration of LV
motion, detected as LVEF or global longitudinal strain
(8,9); however, these changes reﬂect profound dam-
age to myocardial function and thus only become
manifest at an advanced stage of the disease. Almost
90% of patients developing anthracycline-mediated
LVEF deterioration never fully recover pre-
treatment LVEF even with heart failure therapies
(31). The identiﬁcation of T2 relaxation-time
prolongation as a very early marker of reversibleFIGURE 4 Continued
Asterisks indicate statistically signiﬁcant statistical differences compared
(A) Fibrosis (%) in the infused area for each group at sacriﬁce. Represen
sacriﬁce. Representative images show CMR native T1-MOLLI with a 550 t
content (normalized to dry weight) in the infused area for each group a
intracardiomyocyte vacuolization. (D) T2-GraSE mapping (ms) in the infus
a 20 to 120 ms mask range. Red arrows mark areas with signiﬁcantly inintracardiomyocyte vacuolization thus has important
clinical implications. Serial T2 mapping might allow
tailored anthracycline dose management, with pa-
tients showing no T2 mapping abnormalities perhaps
able to receive further doses, even beyond currently
accepted high cardiotoxicity limits, without
increasing the risk of future LV dysfunction. This
could be especially helpful for patients requiring high
anthracycline doses to halt cancer progression. There
is also the potential to monitor and possibly modify
anthracycline therapy in vulnerable populations,
such as patients with pre-existing myocardial disease;
pediatric or geriatric patients; smokers; obese or
sedentary patients; patients consuming alcohol;
or patients with hypertension, diabetes, or hyper-
cholesterolemia (8). The chemotherapy dose-
management potential of serial T2 mapping is
supported by the ﬁnding that cessation of doxoru-
bicin therapy upon detection of T2 mapping abnor-
malities prevented progression to LV motion
deterioration or ﬁbrosis development and led to
regression of cardiomyocyte vacuolae formation.
Another potential application of serial T2 mapping
is decision making about heart failure therapy initia-
tion (e.g., with beta-blockers and/or ACE inhibitors).
This is highly signiﬁcant, because a major predictor of
therapeutic myocardial recovery is the time elapsed
between anthracycline therapy and cardiotoxicity
diagnosis (32). Cardinale et al. (32) found that only
42% of patients with anthracycline-induced car-
diotoxicity fully recovered LV function in response to
heart failure therapy; in that study, the percentage of
responders decreased progressively as the time from
the end of anthracycline therapy to the start of heart
failure treatment increased. Therefore, early detec-
tion and prompt treatment of cardiotoxicity is crucial
to ensuring substantial recovery of cardiac function.
With current approaches (based on LVEF and global
longitudinal strain), the mean interval from the end
of anthracycline therapy to the detection of car-
diotoxicity is 3.5 months (31). The ability to identify
patients at a much earlier stage would allow earlier
initiation of heart failure therapy and would thus
prevent many cases of overt LV dysfunction.with week 0 for each time point: *p < 0.05, **p < 0.01, ***p < 0.001, or nonsigniﬁcant (NS).
tative images show Sirius Red staining. (B) ECV (%) in the infused area for each group at
o 1,750 ms masked range. Red arrows mark areas with signiﬁcantly increased signal. (C) Water
t sacriﬁce. Representative hematoxylin and eosin images are shown. Black arrows mark
ed area for each group at sacriﬁce. Representative images show CMR T2-GraSE mapping with
creased signal. Abbreviations as in Figures 2 and 3.
CENTRAL ILLUSTRATION Serial CMR Evaluations During On-(Anthracycline) Treatment Allows Very Early
Detection of Subtle Myocardial Damage
Galán-Arriola, C. et al. J Am Coll Cardiol. 2019;73(7):779–91.
Isolated T2 relaxation times prolongation (with normal T1, extracellular volume [ECV], and left ventricular [LV] motion) is able to identify intracardiomyocyte
vacuolization, the earliest cardiotoxic event. Stopping anthracycline therapy at this early time point results in no progression to LV motion abnormalities and
normalization of T2 values (corresponding to vacuolae regression). These phenomena support that T2 mapping identiﬁes anthracycline-induced cardiotoxicity at a
reversible stage of the disease. If anthracycline therapy is not halted, T1 mapping and ECV become pathological at a stage where LV motion is already deteriorated.
Serial multiparametric cardiac magnetic resonance (CMR) might serve to implement a personalized treatment approach for patients undergoing anthracycline
therapy to prevent cardiotoxicity.
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788T2 mapping is an accurate technique for the
detection and quantiﬁcation of myocardial edema
(10). We have previously used T2 mapping to char-
acterize the edematous reaction of porcine (11,25,33)
and human (12) myocardium to ischemia/reperfu-
sion. T2 relaxation time prolongation correlates with
increased myocardial water content (10), but by itself
does not differentiate between intracellular and
extracellular edema. Our multiparametric approach,
combining T2 mapping with T1 mapping and ECV
fraction quantiﬁcation, here allowed us to deﬁne the
spatial location of increased myocardial water.
T2 mapping prolongation in the absence of T1mapping or T1-based ECV changes is highly sugges-
tive of intracellular edema formation. Intracellular
vacuolization is an early change in the anthracycline-
injured myocardium, identiﬁed as a pre-apoptotic
phenomena in animal models and human biopsies
(5–7,34). Our analysis records not only in vivo
changes in T2 mapping, but also the very early pres-
ence of intracardiomyocyte vacuolization, before the
appearance of LV functional abnormalities. At the
end of follow-up in animals undergoing the full
doxorubicin protocol (5 biweekly injections and
follow-up to 16 weeks), T2 relaxation times were even
longer than at early stages and were accompanied by
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789signiﬁcant T1 relaxation-time prolongation, a signiﬁ-
cantly elevated T1-based ECV fraction, and patchy
LGE. The pathological correlate at this end-stage of
the disease was the presence of larger and more
numerous intracardiomyocyte vacuoles accompanied
by intense extracellular matrix remodeling and
diffuse ﬁbrosis.
Our results are in line with those reported by Far-
had et al. (26). Using a mouse model of anthracycline-
induced cardiotoxicity, these authors found that
5 weekly doxorubicin injections induced early pro-
longation of T2 relaxation times accompanied by
intracellular vacuolization (26). This study and ours
conﬁrm the feasibility of in vivo noninvasive identi-
ﬁcation of vacuolae formation inside cardiomyocytes
as a direct toxic effect of anthracyclines in 2 different
species. However, Farhad et al. (26) found that T2
mapping abnormalities were associated with concur-
rent T1 relaxation-time prolongation and expanded
extracellular space on electron microscopy images, a
ﬁnding not observed in our analysis until later dis-
ease stages. This indicates that we identiﬁed doxo-
rubicin cardiotoxic effects at an earlier disease stage,
when only intracardiomyocyte changes were present,
with preservation of the extracellular space. Our
weekly protocol was able to identify the onset of
cardiac damage, whereas Farhad et al. (26) performed
the ﬁrst scan at the end of the doxorubicin protocol,
thus missing the earliest on-treatment tissue
composition changes. In another study, Hong et al.
(30) used a rabbit model of doxorubicin-induced
cardiotoxicity to study the evolution of changes in
T1 mapping and T1-based ECV, but did not include T2
mapping. These authors found that T1 relaxation-
time prolongation occurred concurrently with ECV
expansion at a time when LVEF had already
deteriorated (albeit not signiﬁcantly vs. baseline).
Histological evaluation revealed intracardiomyocyte
vacuolization and interstitial ﬁbrosis, indicating that
this time point corresponds to more advanced disease
stage than that identiﬁed by us.
To date, very few studies have used a serial mul-
tiparametric CMR strategy including T2 mapping in
patients undergoing anthracycline therapy. Several
authors have reported CMR ﬁndings in patients
treated with anticancer therapies (16–19,35,36). In
some of these studies, increased ECV coincided with
cardiac function deterioration. Few studies have re-
ported serial CMR examinations before and after
anthracycline exposure, and in most of them,
CMR was performed only after completion of
anthracycline administration, thus missing early
changes occurring during treatment (37–40). Morerecently, Schulz-Menger’s group (41) reported the
ﬁndings of serial multiparametric CMR examinations
in a cohort of 30 sarcoma patients on high anthracy-
cline regimes. Patients underwent comprehensive
T2/T1 mapping and ECV assessment before treatment,
48 h after the ﬁrst dose, and after ﬁnishing the
anticancer therapy; 30% of patients developed car-
diotoxicity. In contrast with our results, T2 mapping
showed no differences between patients developing
cardiotoxicity and those who did not, although both
groups showed a nonsigniﬁcant trend toward
increased T2 relaxation times over time. ECV did not
change over time. Interestingly, patients who subse-
quently developed cardiotoxicity had signiﬁcantly
shortened T1 relaxation times 48 h after the ﬁrst dose.
In our study, we observed no drop in T1 relaxation
time after doxorubicin dosing; however, this might
reﬂect the performance of CMR examinations 1 week
after dosing in our protocol and not after 48 h as in
the study by Muehlberg et al. (41).
Currently, the performance of frequent surveil-
lance, comprehensive, multiparametric, contrast-
enhanced CMRs as part of routine care is likely not
feasible given the high volume of patients receiving
anthracycline-based chemotherapy, high cost, and
lack of access to CMR capabilities. We speculate that
the development of ultra-fast CMR protocols able to
gather the minimum info required for this screening
might help alleviate these limitations. In the mean-
time, this CMR strategy might be offered for those
patients at high risk for developing anthracycline-
induced cardiotoxicity (8).
STUDY LIMITATIONS. One potential limitation of the
present study is the intracoronary doxorubicin
administration route, contrasting the intravenous
route used in cancer patients. In the pig, the intra-
venous route requires very high doxorubicin doses
that result in signiﬁcant myelosuppression and
compromise the experimental setting (42). The
intracoronary approach in the pig model was
described by Christiansen et al. (23) and has been
validated by several imaging approaches as a valid
alternative. In this study, all animals showed a very
similar behavior in terms of time to intra-
cardiomyocyte edema and time to LVEF fall. In the
clinical setting, this is expected to be more variable.
In addition, the time window between T2 relaxation
time prolongation and LVEF fall (3 weeks) appears
narrow to be picked-up in the clinical setting. We
speculate that this time window might be signiﬁ-
cantly wider in patients due to the more concealed
evolution of the disease but this is to be demon-
strated in the clinics.
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: T2 mapping abnormalities
identiﬁed by CMR imaging in the presence of normal
T1, ECV, and LV wall motion correlate with
cardiomyocyte vacuolization at an early and reversible
stage of anthracycline-induced cardiotoxicity.
TRANSLATIONAL OUTLOOK: Prospective trials of
chemotherapeutic strategies guided by serial T2
mapping could incorporate earlier cardiac intervention
to preserve ventricular function in those with early
cardiotoxicity and higher cumulative anthracycline
therapy for those without evidence of toxicity.
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790CONCLUSIONS
In a large animal model of anthracycline-induced
cardiotoxicity, we show that the earliest CMR on-
treatment event is a prolongation of T2 relaxation
time. T1 mapping and T1-based ECV are normal at this
early time point and do not change until later in the
cardiotoxic process. At this early stage, T2 mapping
abnormalities correspond to intracardiomyocyte
edema secondary to doxorubicin-induced vacuoliza-
tion, unaccompanied by any extracellular alteration.
Early identiﬁcation of intracardiomyocyte edema
from T2 mapping abnormalities has prognostic im-
plications, because stopping doxorubicin treatment
upon detection of this early CMR marker stops the
progression of LV dysfunction and triggers regression
of intracardiomyocyte vacuolization. Serial multi-
parametric T2 mapping during treatment has the po-
tential to support personalized anthracycline
regimes.
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